oncology – Page 9 – pharmaceutical daily

January 7, 2019 Off

Mirati and BMS to combine sitravatinib and nivolumab for certain non-small cell lung cancer patients in Mirati’s expected Phase 3 trial

Mirati Therapeutics and Bristol-Myers Squibb will work together on evaluating the combination of sitravatinib and nivolumab (OPDIVO), in Mirati’s planned Phase 3 trial in second line non-small cell lung cancer (NSCLC) patients who have progressed following treatment with a platinum-based regimen and a checkpoint inhibitor.

January 7, 2019 Off

AstraZeneca pays $15 million to its partner Sosei Group, as it hits milestone in development of cancer candidate

By Dino Mustafić

AstraZeneca has reached a clinical development milestone with immuno-oncology candidate AZD4635, thus triggering a $15 million payment to its partner, Sosei Group.

January 7, 2019 Off

4D pharma to test its diverse cancer settings Live Biotherapeutic oncology pipeline with University of Texas MD Anderson Cancer Center

By Dino Mustafić

4D pharma and The University of Texas MD Anderson Cancer Center will together work on testing 4D’s Live Biotherapeutic oncology pipeline across a range of cancer settings, the company said on Monday in a press release

January 7, 2019 Off

Sanofi to pay Regeneron $462 million as companies restructure immuno-oncology agreement for more independence in each research

By Dino Mustafić

Regeneron Pharmaceuticals and Sanofi restructure immuno-oncology agreement from 2015, where Regeneron retains full rights to all its other investigational immunooncology programsto, while Sanofi is able to independently chase own immuno-oncology programs.

January 4, 2019 Off

ADC Therapeutics doses first patient with metastatic solid tumor in clinical test of ADCT-301

By Dino Mustafić

ADC Therapeutics, an oncology drug discovery and development company, has dosed first patient in its Phase Ib clinical trial of ADCT-301 in patients with selected solid tumors that are locally advanced or metastatic.

January 4, 2019 Off

Basilea plans investments in R&D, with earnings from Cresemba and Zevtera sale

By Dino Mustafić

Basilea Pharmaceutica’s CEO David Veitch, will present at the 37th Annual J. P. Morgan Healthcare Conference on January 10, 2019, where he’ll describe both the progress made during 2018 and the priorities for 2019 to deliver on the key elements of Basilea’s strategy for continued value creation, the company said Friday.

December 21, 2018 Off

ObsEva in third phase testing looks at long term administration of linzagolix

By Dino Mustafić

ObsEva is evaluating long term administration of linzagolix in two dosing regimens with recruited patients for third phase of testing oral gonadotropin releasing hormone (GnRH) receptor antagonist Linzagolix.

December 21, 2018 Off

Novartis in $2.1 billion Endocyte buy, adds to its oncology pipeline

By Dino Mustafić

In addition to yesterda’s announcement of moving to buy CAR-T cell producer CellforCure from LFB, Novartis today announced that it acquired another biopharmaceutical company focused on developing radioligand and CAR-T therapies for cancer treatment, the US based Endocyte, Inc.

December 20, 2018 Off

GenomOncology names CEO

By Dino Mustafić

GenomOncology, a technology solution provider for oncology, named Brad Wertz as the new Chairman and Chief Executive Officer (CEO), who’ll assume the position from the start of year 2019. Wertz has been a founding investor and chairman of the board since the beginning, and has increased his involvement as the company has grown over the past two years.

December 19, 2018 Off

AZ nets $70M after FDA’s new approval for Lynparza

By Dino Mustafić

AstraZeneca and Merck’s work on Lynparza is looking at mroe financial return after the US Food and Drug Administration (FDA) approved it for for 1st-line maintenance therapy in BRCA-mutated advanced ovarian cancer.